Remove Development Remove Gene Remove Gene Therapy Remove Reagent
article thumbnail

Sartorius upscales gene therapy prowess with $2.6bn Polyplus acquisition

Pharmaceutical Technology

The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. Polyplus, based in Strasbourg, France, produces key components in the production of viral vectors used in cell and gene therapies.

article thumbnail

£7M financing to drive commercialisation in cell and gene therapy 

Drug Discovery World

Mike Evans, Chair of MIP Discovery, said: “MIP Discovery’s synthetic affinity reagents offer an innovative alternative to antibodies, and are better suited for downstream processing of advanced therapies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

MIP Discovery raises £7m to drive commercialization in cell and gene space

BioPharma Reporter

MIP Discovery, a developer of non-biological affinity reagents designed to accelerate the production of cell and gene therapies, has closed a Â7 million Series A financing round, led by Mercia Ventures.

Gene 97
article thumbnail

FDA INTERACT Meetings: Early Interactions for Cell and Gene Therapy Sponsors

Camargo

Advances in scientific knowledge and growth in the cell and gene therapy space have led to a new and exciting era of medicine for patients, as well as a new motivation for regulators to provide clear, efficient pathways for product developers. Background: The Advancement of Cell and Gene Therapies.

article thumbnail

Regulatory Trends in Cell and Gene Therapies

Advarra

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

article thumbnail

Expert view: What’s next for cell and gene therapy?

Drug Discovery World

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? This issue has become a key focus for the ISCT, and we have been working to identify and develop initiatives to help alleviate these shortages.” The solution?

article thumbnail

Key Trends in Non-Viral Transfection Market

Roots Analysis

Given the limitations of viral transfection as well as the apparent immunogenicity and cytotoxicity concerns associated with these vectors , demand for alternative gene drug vehicles is increasing. Currently, highest number of patent for non-viral transfection reagents and systems is filed in North America region.

Reagent 52